ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.5115
0.25%
Brent Oil
82.245
0.15%
Bitcoin
65,942.78
-1.04%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ablynx NV ADS (delisted) (ABLX)

  7. Ablynx NV ADS (delisted) (ABLX) Noticias

ABLX

Ablynx NV (ABLX)

Ablynx NV ADS (delisted)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ABLX
FechaHoraFuenteTítuloSímboloCompañía
19/06/201800:00GlobeNewswireSANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURENASDAQ:ABLXAblynx NV ADS (delisted)
28/05/201800:05GlobeNewswirePUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...NASDAQ:ABLXAblynx NV ADS (delisted)
25/05/201812:00GlobeNewswireNOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020NASDAQ:ABLXAblynx NV ADS (delisted)
17/05/201800:00GlobeNewswireABLYNX ANNOUNCES WARRANT EXERCISENASDAQ:ABLXAblynx NV ADS (delisted)
14/05/201801:57Dow Jones NewsSanofi-Ablynx Deal Goes AheadNASDAQ:ABLXAblynx NV ADS (delisted)
14/05/201801:00GlobeNewswireSANOFI AND ABLYNX ANNOUNCE THE SUCCESSFUL RESULTS OF THE INITIAL TENDER OFFER PERIOD FOR ABLYNX AND COMMENCEMENT OF SQUEEZE-O...NASDAQ:ABLXAblynx NV ADS (delisted)
30/04/201800:00GlobeNewswireABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIb RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171NASDAQ:ABLXAblynx NV ADS (delisted)
29/03/201800:00GlobeNewswirePREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018NASDAQ:ABLXAblynx NV ADS (delisted)
26/03/201800:00GlobeNewswireABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSNASDAQ:ABLXAblynx NV ADS (delisted)
02/03/201800:00GlobeNewswireABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTIONNASDAQ:ABLXAblynx NV ADS (delisted)
01/03/201804:19Dow Jones NewsSanofi Receives Antitrust Clearances in U.S., Germany for Ablynx AcquisitionNASDAQ:ABLXAblynx NV ADS (delisted)
28/02/201800:00GlobeNewswireABLYNX ANNOUNCES CONVERSION OF BONDSNASDAQ:ABLXAblynx NV ADS (delisted)
22/02/201800:00GlobeNewswireABLYNX ANNOUNCES 2017 FULL YEAR RESULTSNASDAQ:ABLXAblynx NV ADS (delisted)
16/02/201800:00GlobeNewswireABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATESNASDAQ:ABLXAblynx NV ADS (delisted)
07/02/201800:00GlobeNewswireABLYNX ANNOUNCES BOARD CHANGESNASDAQ:ABLXAblynx NV ADS (delisted)
30/01/201802:02Dow Jones NewsSanofi To Acquire Belgian Biotech -- WSJNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201804:59Dow Jones NewsNovo Nordisk Confirms It Will Not Make Revised Bid for AblynxNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201804:54Dow Jones NewsSanofi to Buy Ablynx for $4.85 Billion -- UpdateNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201802:06Dow Jones NewsSanofi to Acquire Ablynx for EUR3.9 BillionNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201801:19GlobeNewswireSANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLIONNASDAQ:ABLXAblynx NV ADS (delisted)
24/01/201800:00GlobeNewswireABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICERNASDAQ:ABLXAblynx NV ADS (delisted)
22/01/201800:00GlobeNewswireABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDSNASDAQ:ABLXAblynx NV ADS (delisted)
09/01/201802:02Dow Jones NewsDrug Firm Rejects $3.13 Billion Offer From Novo Nordisk -- WSJNASDAQ:ABLXAblynx NV ADS (delisted)
08/01/201806:25GlobeNewswireABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUT...NASDAQ:ABLXAblynx NV ADS (delisted)
08/01/201801:30Dow Jones NewsBelgium's Ablynx Rejects EUR2.6 Billion Bid From Novo NordiskNASDAQ:ABLXAblynx NV ADS (delisted)
04/01/201800:00GlobeNewswireABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCENASDAQ:ABLXAblynx NV ADS (delisted)
27/12/201700:00GlobeNewswireNOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTIONNASDAQ:ABLXAblynx NV ADS (delisted)
21/12/201700:00GlobeNewswireABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMABNASDAQ:ABLXAblynx NV ADS (delisted)
12/12/201706:40GlobeNewswireABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTPNASDAQ:ABLXAblynx NV ADS (delisted)
07/12/201700:00GlobeNewswireABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLO...NASDAQ:ABLXAblynx NV ADS (delisted)
 Showing the most relevant articles for your search:NASDAQ:ABLX

Su Consulta Reciente

FX
EURUSD
Euro vs US Dollar
PM
XAUUSD
Gold vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MRK
Merck
AMEX
SPY
SPDR S&P 500
FX
USDMXN
US Dollar vs MXN
NYSE
DIS
Walt Disney
NYSE
BAC
Bank of America
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
NASDAQ
TSLA
Tesla
USOTC
ADDYY
Adidas (QX)
CCOM
US500
US 500
USI
USTECH100
US Tech 100
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados